Clrpharmaceuticals Palwal, Haryana

POLIVY is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have had at least 2 prior therapies.

Olaparib is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers

Olaparib is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers

Packaging Size : Other

Packaging Type : Other

Purity : Other

Durvalumab[1] (trade name imfinzi) is an fda-approved immunotherapy for cancer, developed by medimmune/astrazeneca.[2] it is a human immunoglobulin g1 kappa (igg1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (pd-l1) with the pd-1 (cd279). Durvalumab is approved for the treatment of patients with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Ponatinib is an oral drug developed by ariad pharmaceuticals for the treatment of chronic myeloid leukemia and philadelphia chromosome–positive acute lymphoblastic leukemia. It is a multi-targeted tyrosine-kinase inhibitor

Condition : New